Maximillian Merz

34PUBLICATIONS
191CO-AUTHORS
Haematological tumoursMedical bacteriologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Aug 10, 2026
Hattrick against Lymphoma with Trispecific CAR T Cells.

|Jul 20, 2026
Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

|Jun 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

|Apr 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve

|Dec 10, 2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.

Lukas Scheller, Xiang Zhou, Henry Loeffler-Wirth

|Nov 07, 2025
Mileage matters: long-distance performance of CARs in multiple myeloma.

Eric M Jurgens, Saad Z Usmani, Maximilian Merz

Pageof 6

Frequent Collaborators

12 joint publications

Vladan Vučinić

9 joint publications

Uwe Platzbecker

7 joint publications

Kristin Reiche

6 joint publications

Nico Gagelmann